NO961087D0 - K-252a derivater som öker neuorotrofin-indusert aktivitet - Google Patents
K-252a derivater som öker neuorotrofin-indusert aktivitetInfo
- Publication number
- NO961087D0 NO961087D0 NO961087A NO961087A NO961087D0 NO 961087 D0 NO961087 D0 NO 961087D0 NO 961087 A NO961087 A NO 961087A NO 961087 A NO961087 A NO 961087A NO 961087 D0 NO961087 D0 NO 961087D0
- Authority
- NO
- Norway
- Prior art keywords
- derivatives
- induced activity
- neurotrophin
- increase
- increase neurotrophin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/122,893 US5468872A (en) | 1993-09-16 | 1993-09-16 | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
PCT/US1994/010495 WO1995007911A1 (en) | 1993-09-16 | 1994-09-16 | K-252a DERIVATIVES WHICH ENHANCE NEUROTROPHIN-INDUCED ACTIVITY |
Publications (3)
Publication Number | Publication Date |
---|---|
NO961087D0 true NO961087D0 (no) | 1996-03-15 |
NO961087L NO961087L (no) | 1996-05-13 |
NO309228B1 NO309228B1 (no) | 2001-01-02 |
Family
ID=22405467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO961087A NO309228B1 (no) | 1993-09-16 | 1996-03-15 | K-252a derivater som öker neurotrofin-indusert aktivitet og anvendelse av slike derivater |
Country Status (14)
Country | Link |
---|---|
US (2) | US5468872A (no) |
EP (1) | EP0719268B1 (no) |
JP (2) | JP3943126B2 (no) |
KR (1) | KR100186912B1 (no) |
AT (1) | ATE203751T1 (no) |
AU (1) | AU693480B2 (no) |
CA (1) | CA2171561C (no) |
DE (1) | DE69427862T2 (no) |
ES (1) | ES2160637T3 (no) |
FI (1) | FI961236A0 (no) |
HU (1) | HU222570B1 (no) |
NO (1) | NO309228B1 (no) |
NZ (2) | NZ274355A (no) |
WO (1) | WO1995007911A1 (no) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3064992A (en) * | 1991-11-08 | 1993-06-07 | University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
DE4243321A1 (de) * | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
EP0675125A1 (en) * | 1994-03-18 | 1995-10-04 | Kyowa Hakko Kogyo Co., Ltd. | A therapeutic agent for thrombocytopenia and indolocarbazole derivatives |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
WO1997005141A1 (en) * | 1995-07-31 | 1997-02-13 | Novartis Ag | Staurosporine analogues |
WO1997005140A1 (en) * | 1995-07-31 | 1997-02-13 | Novartis Ag | Trindene compounds |
US5808060A (en) * | 1995-12-11 | 1998-09-15 | Cephalon, Inc. | Fused isoindolones |
UA67725C2 (en) | 1996-06-03 | 2004-07-15 | Cephalon Inc | K-252a derivatives and a method for improvement of functioning and cell survival enhancement |
US6875865B1 (en) | 1996-06-03 | 2005-04-05 | Cephalon, Inc. | Selected derivatives of K-252a |
ES2194385T3 (es) | 1997-12-31 | 2003-11-16 | Cephalon Inc | Derivados del k-252a 3'-epimeros. |
US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6013646A (en) * | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
US7795246B2 (en) * | 1998-08-06 | 2010-09-14 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
ES2288042T3 (es) | 1998-09-25 | 2007-12-16 | Cephalon, Inc. | Uso de pirrolocarbazoles condensados para prevenir/tratar daños de las celulas ciliadas sensoriales y neuronas cocleares. |
EP1101113A4 (en) * | 1999-06-09 | 2002-05-08 | Ljl Biosystems Inc | CELL SIGNALING TESTS |
US6472385B1 (en) * | 1999-08-09 | 2002-10-29 | Trustees Of Darmouth College | Compositions and methods to enhance cancer chemotherapy in p53 defective tumors |
FR2798931B1 (fr) * | 1999-09-22 | 2001-11-16 | Oreal | Nouveaux composes indoliques, leur utilisation pour la teinture et le maquillage des matieres keratiniques, compositions les contenant et procedes de teinture |
US7129250B2 (en) | 2000-05-19 | 2006-10-31 | Aegera Therapeutics Inc. | Neuroprotective and anti-proliferative compounds |
US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
US6610727B2 (en) | 2000-10-06 | 2003-08-26 | Bristol-Myers Squibb Company | Anhydro sugar derivatives of indolocarbazoles |
US6653290B2 (en) * | 2000-10-06 | 2003-11-25 | Bristol-Myers Squibb Company | Tumor proliferation inhibitors |
US6555677B2 (en) | 2000-10-31 | 2003-04-29 | Merck & Co., Inc. | Phase transfer catalyzed glycosidation of an indolocarbazole |
WO2002077255A1 (en) | 2001-03-22 | 2002-10-03 | Bristol-Myers Squibb Company | Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles |
US7018999B2 (en) * | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
US20040186044A1 (en) * | 2002-11-06 | 2004-09-23 | Cosgaya Jose Miguel | Modulation of myelination by interaction with P75 and TRK receptors |
US8066997B2 (en) * | 2002-12-20 | 2011-11-29 | Anders Nykjaer | Modulation of activity of neurotrophins |
HUE025347T2 (en) | 2003-03-19 | 2016-02-29 | Biogen Ma Inc | NOGO receptor binding protein |
ES2395094T3 (es) | 2004-06-24 | 2013-02-08 | Biogen Idec Ma Inc. | Tratamiento de afecciones que implican la desmielinización |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
PT1904104E (pt) | 2005-07-08 | 2013-11-21 | Biogen Idec Inc | Anticorpos sp35 e suas utilizações |
US20080021013A1 (en) * | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
US8642040B2 (en) | 2006-07-24 | 2014-02-04 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
PT2120997T (pt) * | 2006-12-21 | 2017-05-05 | H Lundbeck As | Modulação da atividade de proneurotrofinas |
US20090155352A1 (en) * | 2007-11-20 | 2009-06-18 | Cephalon, Inc. | Microemulsion containing indolocarbazole compound and dosage forms containing the same |
ES2326459B1 (es) | 2008-04-08 | 2010-05-28 | Universidad De Oviedo | Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos. |
EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
CN102264398B (zh) * | 2008-12-22 | 2013-12-18 | 克雷毕里斯股份有限公司 | 合成吲哚并咔唑化合物的聚合物缀合物 |
CN103242404A (zh) * | 2012-02-03 | 2013-08-14 | 复旦大学 | N-鼠李糖基苯并咔唑化合物及其合成方法和在制药中的用途 |
CA2873623C (en) | 2012-05-14 | 2021-11-09 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
CN103012417B (zh) * | 2013-01-08 | 2015-01-07 | 中国科学院昆明植物研究所 | 黄皮属植物中的咔唑生物碱,以其为抗肿瘤活性成分的药物组合物,其制备方法和应用 |
MX2017009038A (es) | 2015-01-08 | 2017-10-25 | Biogen Ma Inc | Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60257652A (ja) * | 1984-06-02 | 1985-12-19 | Canon Inc | 画像処理装置 |
US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
JPH0826036B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
US4735939A (en) * | 1987-02-27 | 1988-04-05 | The Dow Chemical Company | Insecticidal activity of staurosporine |
EP0303697B1 (en) * | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JPH07113027B2 (ja) * | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
DE3803620A1 (de) * | 1988-02-06 | 1989-08-17 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
DE3835842A1 (de) * | 1988-10-21 | 1990-04-26 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US5231001A (en) * | 1991-03-14 | 1993-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
IE921315A1 (en) * | 1991-07-03 | 1993-01-13 | Regeneron Pharma | Method and assay system for neurothrophin activity |
AU3064992A (en) * | 1991-11-08 | 1993-06-07 | University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
JPH05247056A (ja) * | 1992-03-03 | 1993-09-24 | Kyowa Hakko Kogyo Co Ltd | インドロカルバゾール誘導体 |
DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
DE4217963A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Verwendung von Indolocarbazolen zur Behandlung von AIDS |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
-
1993
- 1993-09-16 US US08/122,893 patent/US5468872A/en not_active Expired - Lifetime
-
1994
- 1994-09-16 KR KR1019960701361A patent/KR100186912B1/ko not_active IP Right Cessation
- 1994-09-16 US US08/307,530 patent/US5516772A/en not_active Expired - Lifetime
- 1994-09-16 AT AT94929228T patent/ATE203751T1/de not_active IP Right Cessation
- 1994-09-16 HU HU9600657A patent/HU222570B1/hu not_active IP Right Cessation
- 1994-09-16 AU AU78363/94A patent/AU693480B2/en not_active Ceased
- 1994-09-16 CA CA002171561A patent/CA2171561C/en not_active Expired - Fee Related
- 1994-09-16 EP EP94929228A patent/EP0719268B1/en not_active Expired - Lifetime
- 1994-09-16 DE DE69427862T patent/DE69427862T2/de not_active Expired - Fee Related
- 1994-09-16 NZ NZ274355A patent/NZ274355A/en not_active IP Right Cessation
- 1994-09-16 JP JP50937995A patent/JP3943126B2/ja not_active Expired - Fee Related
- 1994-09-16 ES ES94929228T patent/ES2160637T3/es not_active Expired - Lifetime
- 1994-09-16 WO PCT/US1994/010495 patent/WO1995007911A1/en active IP Right Grant
-
1996
- 1996-03-15 FI FI961236A patent/FI961236A0/fi unknown
- 1996-03-15 NO NO961087A patent/NO309228B1/no not_active IP Right Cessation
-
1997
- 1997-01-08 NZ NZ314037A patent/NZ314037A/xx not_active IP Right Cessation
-
2005
- 2005-04-26 JP JP2005127746A patent/JP2005220141A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR100186912B1 (ko) | 1999-05-01 |
CA2171561A1 (en) | 1995-03-23 |
NZ274355A (en) | 1997-03-24 |
ATE203751T1 (de) | 2001-08-15 |
NZ314037A (en) | 2000-09-29 |
AU693480B2 (en) | 1998-07-02 |
JPH09502730A (ja) | 1997-03-18 |
HUT74679A (en) | 1997-01-28 |
NO961087L (no) | 1996-05-13 |
ES2160637T3 (es) | 2001-11-16 |
HU222570B1 (hu) | 2003-08-28 |
WO1995007911A1 (en) | 1995-03-23 |
EP0719268B1 (en) | 2001-08-01 |
KR960704894A (ko) | 1996-10-09 |
CA2171561C (en) | 1999-08-03 |
US5468872A (en) | 1995-11-21 |
JP3943126B2 (ja) | 2007-07-11 |
US5516772A (en) | 1996-05-14 |
FI961236A (fi) | 1996-03-15 |
JP2005220141A (ja) | 2005-08-18 |
FI961236A0 (fi) | 1996-03-15 |
EP0719268A1 (en) | 1996-07-03 |
DE69427862T2 (de) | 2002-04-11 |
HU9600657D0 (en) | 1996-05-28 |
AU7836394A (en) | 1995-04-03 |
DE69427862D1 (de) | 2001-09-06 |
NO309228B1 (no) | 2001-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO961087L (no) | K-252a derivater som öker neuorotrofin-indusert aktivitet | |
DK0640086T3 (da) | Mercaptoacetylamido-pyridazo[1,2-a][1,2]diazepin-derivateranvendelige som enkephalinase- og ACE-inhibitorer | |
ATE271041T1 (de) | Analoga von duocarmycin and cc-1065 | |
FI941452A (fi) | Yhdisteitä, jotka lisäävät muiden sytotoksisten aineiden kasvaimenvastaista aktiivisuutta | |
NO944430L (no) | 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer | |
ITMI930699A1 (it) | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale | |
ES2089687T3 (es) | 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa. | |
BR9707659A (pt) | Pirrol(2,3-C) carbarzol-6-onas que potencializam atividade atividade de interferon gama | |
IT1264530B (it) | Impiego dei polisaccaridi nelle neuropatie atrofico degenerative | |
ES2177783T3 (es) | Uso de la gabapentina y sus derivados en el tratamiento de mania y desorden bipolar. | |
AU2883689A (en) | The use of moclobemide to treat or prevent cognitive disorders | |
DK0706385T3 (da) | Anvendelse af isovaleramid som et mildt anxiolytisk og et mildt sedativt middel | |
ES2062145T3 (es) | 1,8-naftiridinas substituidas. | |
FI954614A (fi) | Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina | |
AU7025087A (en) | Pharmaceutical compositions for the therapy of cerebropathies on functional and organic base | |
DE69202895D1 (de) | Feuchtmittelzusatz und Anwendung desselben. | |
MX9307679A (es) | Derivados de furanona utiles en terapia. | |
ZA893606B (en) | Use of diazepinones for treating disorders of the microcirculation | |
ES2019729A6 (es) | Estructura tridimensional para mobiliario. | |
FR2707987B1 (fr) | Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique . | |
RO102805A2 (ro) | Compozitie vitaminizanta pentru copii | |
IT213831Z2 (it) | Dispositivo di bloccaggio per rotelle di poltrone scrivanie esimili. | |
NO912276L (no) | Heparinfragmenter som hemmere av proliferasjon av glatte muskelceller. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |